Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Analysts

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has received an average rating of “Hold” from the twelve brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $6.64.

A number of equities analysts have issued reports on MRVI shares. Stifel Nicolaus set a $5.00 target price on shares of Maravai LifeSciences in a report on Friday, March 21st. Morgan Stanley cut their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 25th. Craig Hallum cut their target price on shares of Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. Robert W. Baird cut their target price on shares of Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating on the stock in a report on Tuesday, May 13th. Finally, UBS Group cut their target price on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a report on Friday, March 21st.

Institutional Investors Weigh In On Maravai LifeSciences

A number of hedge funds have recently made changes to their positions in MRVI. Alyeska Investment Group L.P. raised its holdings in shares of Maravai LifeSciences by 145.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company’s stock valued at $29,045,000 after buying an additional 3,161,072 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Maravai LifeSciences by 17,912.9% during the fourth quarter. Marshall Wace LLP now owns 2,778,497 shares of the company’s stock valued at $15,143,000 after acquiring an additional 2,763,072 shares during the period. Philosophy Capital Management LLC acquired a new position in shares of Maravai LifeSciences during the first quarter valued at approximately $5,731,000. Massachusetts Financial Services Co. MA increased its stake in shares of Maravai LifeSciences by 29.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company’s stock valued at $25,420,000 after acquiring an additional 1,062,485 shares during the period. Finally, 12 West Capital Management LP increased its stake in shares of Maravai LifeSciences by 8.0% during the first quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company’s stock valued at $27,672,000 after acquiring an additional 930,000 shares during the period. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Stock Performance

Shares of MRVI stock opened at $2.77 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.17 and a current ratio of 5.96. Maravai LifeSciences has a one year low of $1.67 and a one year high of $10.03. The company’s 50-day simple moving average is $2.21 and its 200-day simple moving average is $3.19. The stock has a market capitalization of $705.15 million, a price-to-earnings ratio of -2.43 and a beta of 0.28.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Maravai LifeSciences had a negative return on equity of 12.91% and a negative net margin of 67.14%. The business had revenue of $46.85 million during the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences’s quarterly revenue was down 26.9% compared to the same quarter last year. Equities analysts anticipate that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.